HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Activating point mutations in K-RAS are extremely common in cancers of the lung, colon, and pancreas and are highly predictive of poor therapeutic response. One potential strategy for overcoming the deleterious effects of mutant K-RAS is to alter its posttranslational modification. Although therapies targeting farnesylation have been explored, and have ultimately failed, the therapeutic potential of targeting other modifications remains to be seen. Recently, it was shown that acetylation of lysine 104 attenuates K-RAS transforming activity by interfering with GEF-induced nucleotide exchange. Here, the deacetylases HDAC6 and SIRT2 were shown to regulate the acetylation state of K-RAS in cancer cells. By extension, inhibition of either of these enzymes has a dramatic impact on the growth properties of cancer cells expressing activation mutants of K-RAS. These results suggest that therapeutic targeting of HDAC6 and/or SIRT2 may represent a new way to treat cancers expressing mutant forms of K-RAS. Implications: This study suggests that altering K-RAS acetylation is a feasible approach to limiting tumorigenic potential. Mol Cancer Res; 11(9); 1072–7. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 1×
“Although HDAC6 was first identified as a tubulin deacetylase (10-12), it has many other”
BackgroundHDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 1×
“Although HDAC6 was first identified as a tubulin deacetylase (10-12), it has many other”
BackgroundIn vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation
Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin‐Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf682 · Cited by 720 · cited 1×
“Although HDAC6 was first identified as a tubulin deacetylase (10-12), it has many other”
BackgroundGenomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290 · cited 1×
“K-RAS protein functions as a monomeric GTPase and can be locked into its GTP-bound activated state by missense point mutation, most commonly at amino acids 12, 13, 61, or 146 (2).”
BackgroundThe Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Lee, Y.-S., Lim, K.-H., Guo, X., Kawaguchi, Y., Gao, Y., Barrientos, T., Ordentlich, P., Wang, X.-F., Counter, C. M., & Yao, T.-P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0188 · Cited by 260 · cited 2×
“A more direct role for HDAC6 in cancer was revealed when HDAC6 null mouse embryonic fibroblasts (MEF) were found to be resistant toH-RAS–induced transformation and that HDAC6 null animals were resistant to 7,12dimethylbenz[a]anthracene (DMBA)-induced skin carcinogenesis,which also involvesmutation ofH-RAS (16).”
Background
Cited by
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
“…exchange, leading to reduced transformation efficiency in cells, and the deacetylases SIRT2 and HDAC6 were shown to regulate the level of acetylation of K-Ras (Yang et al., 2013), suggesting that inhibitors of these enzymes might have an effect on the oncogenic potential of mutant K-Ras tumors.”
BackgroundOff-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 754
Selective Sirt2 inhibition by ligand-induced rearrangement of the active site
Rumpf, T., Schiedel, M., Karaman, B., Roessler, C., North, B. J., Lehotzky, A., Oláh, J., Ladwein, K. I., Schmidtkunz, K., Gajer, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7263 · Cited by 297
Sirtuins in Epigenetic Regulation
Jing, H., & Lin, H. (2015) · Chemical Reviews · doi:10.1021/cr500457h · Cited by 270
Metadata
- Authors
- Yang, M. H., Laurent, G., Bause, A. S., Spang, R., German, N., Haigis, M. C., & Haigis, K. M.
- Venue
- Molecular Cancer Research
- Published
- 2013-09-01
- Volume
- 11
- Issue
- 9
- Pages
- 1072-1077
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2171236206
- Cited by
- 141
- References
- 5
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-13-0040-t
- The paper
- Yang, M. H., Laurent, G., Bause, A. S., Spang, R., German, N., Haigis, M. C., & Haigis, K. M. (2013). HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-13-0040-t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.